Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

We recently published a list of 10 Most Profitable Value Stocks to Buy Now. In this article, we are going to take a look at ...

Xponance Inc. grew its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 4.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The ...

Dividend stocks have remained a popular choice among investors due to the steady income they provide, becoming even more ...

Pfizer’s shares (currently trading at $26.70) have posted a disappointing 10.2% loss, well below the S&P 500’s 3.8% gain.

Shrewd investors know that bear markets open up great opportunities to pick up shares of excellent companies from the ...

PFIZER INC (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 95% based on the firm’s underlying fundamentals and the stock’s valuation.

Guggenheim analyst Vamil Divan maintained a Buy rating on Pfizer (PFE – Research Report) yesterday. The company’s shares closed yesterday at ...

Representative Julie Johnson (D-Texas) recently sold shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March 12th, the Representative disclosed that they had sold between $1,001 and $15,000 ...

underscoring why the next few years may see further stock price recovery headwinds. These reasons are also why PFE has guided an underwhelming FY2025 guidance with revenues of $62.5B (-1.7% YoY ...